GlassScriptPhysician profile
Jonathan P Axel
NPI 1013082635
$1,342.83
in general payments reported to CMS, 2019-2025
12 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $121 · 2021: $172 · 2022: $213 · 2023: $267 · 2024: $156 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.43 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $707.59 | 2019-2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $196.27 | 2022-2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $141.15 | 2019-2023 | Symbicort |
| Mylan Specialty L.P. | $99.97 | 2019-2023 | Yupelri |
| Amgen INC. | $52.58 | 2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $30.37 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.87 | 2024 | Glassia |
| Jazz Pharmaceuticals INC. | $21.85 | 2023 | |
| Genzyme Corporation | $20.94 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.85 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.53 | 2020 | |
| Electromed, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Axel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.